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ABSTRACT
Amplification and/or overexpression of the human epidermal growth factor 2 
(HER2) oncogene occurs in about 13–15% of invasive breast cancer and triggers 
breast cancer cell proliferation, survival and metastatic progression. Around half of 
all breast cancers with HER2 overexpression co-express hormone receptors (HR) such 
as those for estrogen and progesterone. Aberrant signaling through HER2 and other 
members of the HER-family mediates endocrine-resistance in estrogen receptor alpha 
(ERα) positive breast cancer. On the other hand, ERα co-expression has been shown 
to attenuate the efficiency of anti-HER2 therapies. These findings indicate that HER2 
and ERα synergize to escape from both anti-ERα and anti-HER2-targeted therapies. 
Rationally designed clinical trials that combine endocrine therapy with anti-HER2 
agents to interfere with HER2/ERα cross-talk have been conducted. However, the 
outcome of these trials suggests that novel therapeutic approaches are needed to 
further improve inhibition of HER2 and other HER-family members in conjunction with 
a more efficient ERα blockade. Here, we demonstrate that carfilzomib and bortezomib 
stabilize the HER2-specific protein tyrosine phosphatase BDP1 leading to decreased 
HER2 autophosphorylation, reduced HER2 activity and subsequently attenuated 
activation of the PI3K/Akt-pathway, together with blockade of ERα expression. We 
further observed that proteasome inhibitors (PIs) reverse autophosphorylation and 
thereby inhibit the activity of constitutively active mutant HER2. We also demonstrate 
that PIs cause cell death in lapatinib and endocrine-resistant HER2+/ER+ breast 
cancer cells. These findings suggest that PIs might have the potential to improve the 
management of HER2+/ER+ breast cancer patients by efficiently disrupting the bi-
directional HER2/ERα cross-talk.
INTRODUCTION
The human epidermal growth factor receptor 2 
(HER2) oncogene is amplified and/or overexpressed in 
around 15% of invasive breast cancer. Breast cancers with 
HER2 gene amplification and/or HER2-overexpression 
are commonly characterized by poor clinical outcome, 
aggressive behaviour, higher recurrence rate and increased 
mortality [1, 2]. Although HER2-targeted therapies 
in combination with chemotherapy have significantly 
improved the treatment and survival of HER2+ breast 
cancer patients [3–10], in clinical practice HER2+ breast 
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cancer patients are not homogeneous in terms of disease 
progression, prognosis and response to therapeutic 
regimens [11]. In particular, co-expression of hormone 
receptors (HR) and especially ER alpha (ERα) appears to 
be a significant predictor of differential sensitivity to anti-
HER2 and chemotherapy based therapies [12]. Data from 
several neoadjuvant studies suggest that the response to 
therapy with anti-HER2 agents markedly depends on HR 
status and ERα expression in particular [8, 9, 12, 13, 14].
In vitro studies based on HER2+ breast cancer 
cell lines with either intrinsic or acquired resistance to 
trastuzumab, lapatinib or both trastuzumab and lapatinib 
have been performed to determine the role of ERα in the 
onset of resistance to HER2-targeted therapies [15]. The 
results of these experiments showed that under sustained 
HER2 inhibition, ERα can rescue HER2+/ER+ cells, and 
that the dynamic switch between HER2 and ERα activity 
plays a central role in determining resistance to lapatinib-
containing treatment regimens [15]. In clinical practice, 
increased ERα activity has also been reported in patients 
with HER2+/ERα+ metastatic breast cancer [16, 17]. 
Thus, these observations indicate that either ERα or HER2 
can function as a major promoter of proliferation and 
survival in HER2+/ER+ breast cancer cells.
Upregulated expression of ERα serves as a survival 
mechanism upon permanent HER2 inhibition, while 
increased signaling through HER2 and/or other members 
of the HER-family has been shown to mediate resistance 
to endocrine therapies in ERα+ breast cancer cells [18, 
19]. Sustained activation of the PI3K/Akt and the Ras/
MAPK pathways through these and other receptors such as 
IGF-R1 is considered to be the most important mechanism 
that leads to endocrine resistance [18, 19]. Phosphorylation 
of ERα and its co-activators by these pathways was found 
to lead to enhanced genomic ERα activity and increased 
expression of ERα-target genes, even in the absence 
of estrogen or in the presence of tamoxifen [20–22]. 
Phosphorylation of co-repressors causes their inactivation 
and export out of the nucleus, thereby increasing 
expression of ERα-target genes [23, 24]. 
Two further mechanisms illustrate how ERα can 
influence HER2 expression to determine tamoxifen 
resistance. First, it was shown that in the presence of the 
transcription factor PAX2 estrogen-ERα and tamoxifen-
ERα complexes directly repress HER2 transcription. Thus, 
inhibition of PAX2 causes tamoxifen resistance through 
ERα-mediated transcriptional up-regulation of HER2 
[25]. Second, the interaction between the co-activator 
HOXB7 and ERα leads to tamoxifen resistance through 
overexpression of the ERα-target genes HER2 and Myc 
[26]. Thus, both reports indicate that HER2 is an ERα-
target gene and that transient up-regulation of HER2 
expression by ERα can cause endocrine resistance [25, 26]. 
In conclusion, these observations highlight the 
importance of dual inhibition of both HER2 and ERα to 
achieve the most efficient antitumor activity in HER2+/
ER+ breast cancer. Clinical studies using endocrine 
therapy combined with HER2-targeting agents have 
already been conducted in an attempt to block HER2 and 
ERα cross-talk [27–30]. However, these trials showed 
only a modest activity of the dual blockade of both ERα 
and HER2. In the more recently reported PERTAIN 
trial advanced HR+/HER2+ breast cancer patients were 
treated with an aromatase inhibitor (AI) and trastuzumab 
either with or without pertuzumab treatment [31]. This 
study has demonstrated that patients receiving additional 
pertuzumab had an increased progression-free survival 
(PFS) [31], confirming that effective suppression of both 
HER2 and ERα are crucial to improve HER2+/HR+ breast 
cancer treatment. Nevertheless, further novel therapeutic 
strategies that more efficiently inhibit both HER2 and 
ERα are required. Furthermore, the observation that 
ERα-mediated transient up-regulation of HER2 leads to 
endocrine resistance suggests that therapeutic regimens 
leading to dual blockade of ERα and HER2 even in ER+ 
breast cancers without HER2 amplification or primarily 
HER2 overexpression might be therapeutically relevant. 
In a previous report we have shown in ER+ breast 
cancer cell lines that the first generation proteasome 
inhibitor (PI) bortezomib decreased expression of ERα and 
HER2 and inhibited signalling pathways responsible for 
induction of endocrine resistance [32]. These observations 
led us to suggest that PIs might be a possible treatment 
option for endocrine therapy resistant ERα+ breast cancers 
and prompted us to investigate further whether PIs can 
target ERα+/HER2-amplified breast cancer cells, as well 
as the mechanisms through which they act. To determine 
whether different PIs act through equivalent mechanisms 
within cells, we performed experiments with bortezomib 
and the second generation PI carfilzomib in parallel. We 
found that carfilzomib and bortezomib markedly inhibit bi-
directional HER2/ERα signaling pathways in HER2+/ER+ 
breast cancer cell lines. Both PIs suppress ERα expression, 
inhibit HER2, and subsequently suppress the downstream 
pathway PI3K/Akt that is a major executor of endocrine 
resistance. Furthermore, these PIs stabilized the HER2-
specific tyrosine phosphatase BDP1, and were thereby 
even able to suppress the activity of a constitutively active 
HER2 variant that is resistant to trastuzumab and lapatinib. 
These findings indicate that PIs substantially disrupt the 
cross-talk between HER2 and ERα signaling pathways 
through mechanisms other than those activated by the 
therapeutic regimens currently used to treat HER2+/ER+ 
breast cancer. While clinical application of bortezomib 
has often been limited due to high toxicity clinical trials 
performed with carfilzomib showed a more favourable 
side effect profile [33], suggesting that carfilzomib might 
have the potential to improve treatment of HER2+/ER+ 
breast cancer patients. Furthermore, these data suggest that 
carfilzomib could also be a treatment option for patients 
with endocrine resistant HER2-/ER+ breast cancer, or for 
patients with mutated HER2. An early phase clinical trial 
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of carfilzomib would therefore be useful to test its value in 
the treatment of advanced breast cancer.
RESULTS
Carfilzomib leads to down-regulation of ERα 
expression and induces cell death in ER+ breast 
cancer cells
Recently, we reported that the first generation PI 
bortezomib inhibits ERα-expression and disrupts signaling 
pathways that mediate resistance to commonly used 
treatment regimens that target ERα [32]. These findings 
led us to hypothesize that PIs might have the potential to 
be a possible treatment option for ERα+ breast cancers, 
including those resistant to endocrine therapy. In the 
present study we have investigated whether the second 
generation PI carfilzomib exerts inhibitory effects on ERα+ 
breast cancer cells equivalent to those of bortezomib, and 
whether both drugs can target endocrine therapy-resistant 
ERα+/HER2-amplified breast cancer cells. 
Induction of cell death upon carfilzomib treatment 
was assessed by quantification of the SubG1 DNA content 
in treated cells and through the use of colony-forming 
assays (Figure 1A, 1B). Notably, after 10 days no surviving 
cells could be detected when MCF7 cells were cultured in 
the presence of 50–100 nM carfilzomib nor when T47D 
cells were treated with 25 nM carfilzomib (Figure 1B). 
Immunoblotting demonstrated that carfilzomib causes 
decreased expression of ERα and decreased levels of 
HER2, as well as inhibition of Akt and MAPK, as indicated 
by reduced amounts of p-AktSer473 and p-ERK1/2 in both 
cell lines (Figure 1C). Collectively, these results indicate 
that carfilzomib has similar effects on ERα+ breast cancer 
cells as those previously reported for bortezomib [32].
Carfilzomib and bortezomib inhibit HER2 
autophosphorylation, block ERα expression and 
cause cell death in ER+/HER2-amplified breast 
cancer cells
To determine whether PIs can act against ERα+ 
breast cancer cells that have intrinsic resistance to endocrine 
therapy regimens, the ER+/HER2+ breast cancer cell lines 
BT474 and MDA-MB-361 were cultured in the presence of 
various carfilzomib or bortezomib concentrations. Induction 
of cell death upon carfilzomib and bortezomib treatment 
was assessed using colony-forming assays (Figure 2A, 2C). 
Apoptosis was monitored by immunoblotting and detection 
of caspase7 and Poly(ADP-ribose)polymerase-1 (PARP1) 
cleavage (Figure 2B, 2D). After 9 days, no surviving cells 
could be detected when BT474 or MDA-MB-361 cells 
were cultured in the presence of carfilzomib concentrations 
higher than 25–50 nM (Figure 2A, 2C, right panels) or 
with bortezomib concentrations higher than 5–10 nM 
(Figure 2A, 2C, left panels). 
Both carfilzomib and bortezomib decreased expression 
of ERα, suppressed HER2 autophosphorylation, and inhibited 
Akt, as indicated by decreased levels of p-HER2Tyr1248, 
p-HER2Tyr1221/1222 and p-AktSer473 (Figure 2B, 2D). Caspase 
and PARP1 cleavage correlate with reduced HER2 
phosphorylation and reduced ERα levels (Figure 2B, 2D).
Activation of HER2 triggers autophosphorylation 
of specific tyrosine residues within its cytoplasmic 
domain, subsequently leading to activation of intracellular 
signaling pathways such as the Ras/MAPK and the 
PI3K/Akt pathways [34]. Protein tyrosine phosphatases 
are important key regulators of HER2 activity [35, 36], 
including the PEST-type protein-tyrosine phosphatase 
BDP1 that inhibits ligand-induced activation of HER2 by 
decreasing HER2 phosphorylation [36, 37]. PEST-type 
proteins are rapidly degraded by the ubiquitin/proteasome 
system [38]. Based on this information, we hypothesized 
that PIs might increase the half-life of BDP1 and other 
PEST-type proteins such as PTPN12 [39] and PTPN13 
[35], thereby decreasing the phosphorylation state and 
reversing the activation of HER2. Accordingly, using 
immunoblotting we found that increased levels of BDP1 
were observed in the presence of increasing carfilzomib 
and bortezomib concentrations and that BDP1 levels and 
the phosphorylation status of HER2 were almost inversely 
related (Figure 2B, 2D).
Notably, only BDP1 but not PTPN12 or PTPN13 
levels were increased within BT474 and MDA-MB-361 cells 
in the presence of PIs (Figure 3). These findings are consistent 
with the notion that decreased HER2 phosphorylation upon 
PI treatment may be mediated by BDP1. 
Carfilzomib and bortezomib-mediated inhibition 
of HER2 phosphorylation, blockade of ERα 
expression and increased levels of BDP1 
correlate temporally with induction of apoptotic 
cell death
The results in Figure 2 were obtained after cells 
had been incubated with PIs for more then 30 hours 
(Figure 2B, 2D) or even several days (Figure 2A, 2C). 
However, quantification of the SubG1 DNA content in 
BT474 cells revealed that cell death in response to PI 
treatment is induced at earlier time points (Figure 4A). 
We therefore investigated whether induction of 
apoptotic cell death as measured by caspase and PARP1 
cleavage correlates temporally with decreased HER2 
phosphorylation, BDP1 up-regulation and decreased 
expression of ERα. To this end, BT474 cells were treated 
with either 25 nM bortezomib or 250 nM carfilzomib, then 
cells were harvested at different time points and analysed 
by immunoblotting (Figure 4B). 
Notably, the experiments showed that increased 
BDP1 levels, decreased HER2 phosphorylation and 
reduced ERα expression occured at earlier time points 
after PI treatment, concomitantly with caspase and 
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PARP1 cleavage. Together these results suggest that PIs 
efficiently inhibit ERα/HER2 cross-talk pathways through 
blocking ERα expression, as well as through inhibiting 
HER2 activation via stabilization of BDP1, which 
leads to the death of ER+/HER2+ breast cancer cells 
(Figure 4C). 
Figure 1: Carfilzomib down-regulates ERα expression and induces cell death in ER+ breast cancer cells. (A) Carfilzomib 
induces cell death in a concentration- and time dependent manner. Cells were cultured in the presence or absence of the indicated carfilzomib 
concentrations. The percentage of SubG1 cells was evaluated at different time points using propidium iodide staining and flow cytometry. 
Mean values ± s.d. of three independent experiments are presented. (B) Equal numbers of T47D and MCF7 cells were seeded on 12-well 
culture plates and treated with the indicated carfilzomib concentrations. After 10 days cells were fixed and stained. (C) T47D and MCF7 
cells were cultured with the indicated carfilzomib concentrations for 32 or 36 hours, respectively. Western blots of protein lysates were 
probed with the indicated antibodies. β-actin served as loading control.
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Figure 2: Carfilzomib and bortezomib inhibit HER2 autophosphorylation, block ERα expression and cause cell death 
in ER+/HER2-amplified breast cancer cells. (A–D) Carfilzomib and bortezomib induce cell death in a concentration-dependent 
manner. (A) and (C) Equal numbers of BT474 or MDA-MB-361 cells were seeded on 12-well culture plates and treated with the indicated 
carfilzomib or bortezomib concentrations. After 10 days cells were fixed and stained. (B) and (D) BT474 and MDA-MB-361 cells were 
cultured in the presence of the indicated carfilzomib and bortezomib concentrations for 32 hours. Western blots of protein lysates were 
probed with the indicated antibodies.
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Knockdown of BDP1 attenuates PI-mediated 
inactivation of HER2 and its downstream target 
Akt
To determine whether BDP1 is functionally involved 
in PI-mediated suppression of HER2 autophosphorylation 
and inhibition of Akt, stable knockdowns of BDP1 were 
performed. 
The efficiency of the shRNAs to inhibit BDP1 
expression within BT474 cells was measured by 
quantitative PCR (Figure 5A, left panel). The two most 
effective shRNAs reduced BDP1 mRNA transcripts 
approximately 30–45 fold after two passages under 
selection (Figure 5A, right panel). BT474 cells stably 
transduced with either BDP1 shRNA k.o.2, k.o.7 or 
with non-targeted scrambled shRNA were then used for 
functional analysis. Immunoblotting revealed that both 
BDP1 knock down cell lines displayed much stronger 
activation of Akt, as indicated by higher levels of 
p-AktSer473 in comparison with their scrambled shRNA 
control counterparts (Figure 5B). BDP1 k.o.7 cells also 
displayed increased endogenous levels of p-HER2Tyr1248 
and p-HER2Tyr1221/1222 in comparison to k.o.2 cells and 
controls. The HER2 downstream target Akt was strongly 
activated in both BDP1 knockdown cells, possibly because 
BDP1 might increase phosphorylation of other HER2 
phosphorylation sites that are important for activation 
of Akt such as p-HER2Tyr1112 and p-HER2Tyr1196 [37] or 
because BDP1 affects the activation status of Akt directly 
by mechanisms other than HER2 inhibition. 
Immunoblotting also revealed that after BDP1 
knockdown, the ability of carfilzomib to decrease HER2 
autophosphorylation and to inhibit Akt activation was 
attenuated, as indicated by higher levels of p-HER2Tyr1248, 
p-HER2Tyr1221/1222 and p-AktSer473 (Figure 5B). In the 
presence of carfilzomib both BDP1 knockout cell lines 
showed decreased amounts of cleaved PARP1 (Figure 5B) 
indicating an insensitivity to PI compared to controls. 
Furthermore, only BDP1 knockout cells formed colonies 
in the presence of carfilzomib concentrations higher than 
50 nM (Figure 5C, 5D). 
These findings indicate that knockdown of BDP1 is 
functionally involved in PI-mediated inhibition of HER2 
and Akt, thereby making BT474 cells less sensitive to PI-
induced cell death.
Establishment of fulvestrant-resistant ERα-
positive breast cancer cells through expression 
of a constitutively active HER2 mutant that is 
resistant to trastuzumab and lapatinib
The observations above show that PIs 
dephosphorylate HER2 and thereby render it inactive, a 
mode of HER2 suppression that differs from inhibitory 
antibodies such as trastuzumab or the tyrosine kinase 
inhibitors (TKIs) lapatinib and neratinib. We therefore 
hypothesized that PIs may be able to inhibit constitutively 
active HER2 mutants that render breast cancer cells 
resistant to commonly used anti-HER2 therapies. To 
investigate this hypothesis we created MCF7 cells that 
Figure 3: Carfilzomib and bortezomib increase the levels of the PEST type protein-tyrosine phosphatase BDP1 
(PTPN18) but not PTPN12 and PTPN13. (A) BT474 and (B) MDA-MB-361 cells were cultured in the presence of the indicated 
carfilzomib (right panels) and bortezomib (left panels) concentrations for 32 hours. Western blots of protein lysates were probed with the 
indicated antibodies.
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Figure 4: Carfilzomib and bortezomib-mediated inhibition of HER2 autophosphorylation, blockade of ERα expression 
and increase in BDP1 levels correlates temporally with induction of apoptotic cell death. (A) Carfilzomib and bortezomib 
induce cell death in a time-dependent manner. BT474 cells were cultured in the presence or absence of the indicated carfilzomib or 
bortezomib concentrations. The percentage of SubG1 cells was evaluated at different time points using propidium iodide staining and flow 
cytometry. Mean values ± s.d. of three independent experiments are presented. (B) BT474 cells were cultured in the presence of 250 nM 
carfilzomib or 25 nM bortezomib. Cells were harvested at the indicated time points. Western blots of protein lysates were probed with the 
indicated antibodies. (C) Schematic model of a possible molecular network regulated by both proteasome inhibitors, based on the results 
of the Western blots and the literature. Continued activation of HER2 has a causal role in tumorigenesis and leads to tumor progression [1, 
2]. Activation of HER2 triggers autophosphorylation of specific tyrosine residues within its cytoplasmic domain, consequently activating 
different intracellular signaling pathways such as Ras-MAPK and the PI3K/Akt axis [34] which determine cell growth, cell survival and 
therapy resistance to endocrine therapies. Different protein tyrosine phosphatases regulate phosphorylation of the HER2 signaling domain 
and are therefore important key regulators of HER2 activity [35, 36]. The PEST-type protein-tyrosine phosphatase BDP1 inhibits ligand-
induced activation of HER2 [36, 37]. PEST sequences cause accelerated degradation by the proteasome/ubiquitin system [38], and PIs 
therefore increase the amount of BDP1 through blocking its proteasomal destruction. This in turn leads to accelarated dephosporylation and 
thereby inactivation of HER2 and its downstream target signaling pathways. Aberrant signaling through HER2 and other members of the 
HER family mediates endocrine resistance in ER+ positive breast cancer. On the other hand ERα co-expression with HER2 attenuates the 
efficiency of anti-HER2-targeted therapies. These findings indicate that HER2 and ERα act in concert to allow breast cancer cells to escape 
from both anti-ERα and anti-HER2-targeted therapies. Besides inhibiting HER2, PIs also suppress ERα protein expression. 
Oncotarget72288www.impactjournals.com/oncotarget
Figure 5: Knockdown of BDP1 attenuates PI-mediated inactivation of HER2 and its downstream target Akt. (A) Stable 
knockdown of BDP1 within BT474 cells was performed by using lentiviral transfer of non-targeted or ten different targeted shRNAs against 
BDP1. After transduction reduced expression of BDP1 in ten BT474 BDP1 k.o. cells was evidenced by qPCR (left panel). The two shRNAs 
(k.o.2 and k.o.7) with the highest potential to decrease BDP1 expression in BT474 cells at passage 2 of puromycin selection were used to 
quantify the degree of knockdown (right panel). (B) BT474 cells either transduced with non-targeted or BT474 k.o.2 and k.o.7 from passage 
2 of puromycin selection were cultured in the presence or absence of carfilzomib for 28 hours. Western blots of protein lysates were probed 
with the indicated antibodies. (C) Equal numbers of BDP1 k.o.2, BDP1 k.o.7 and negative control scramble BT474 cells were seeded on 
12-well culture plates and treated with the indicated carfilzomib concentrations (right panels). After 9 days cells were fixed and stained. 
(D) Macroscopic photos are shown of the fixed cell colonies for BT474 cells either untreated or treated with the indicated carfilzomib 
concentration. Bar 100 µm.
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ectopically express either wild-type (wt), HER2 or HER2 
insYVMA a constitutively active mutant that is resistant 
to trastuzumab and lapatinib [40]. Ectopic HER2 protein 
expression was monitored by immunohistochemical 
staining (Figure 6A). 
Immunoblotting showed that the constitutively 
active HER2 insYVMA expressing MCF7 cells 
displayed markedly increased levels of p-HER2 Tyr1248, 
p-HER2Tyr1221/1222, p-AktSer473 and p-ERK1/2 in comparison 
to HER2 wt cells, even though the HER2 insYVMA 
cells expressed slightly lower amounts of HER2 protein 
(Figure 6B). Notably, MCF7 HER2 insYVMA and HER2 
wt displayed reduced levels of ERα in comparison to the 
negative control parental cells (Figure 6B), consistant with 
observations made previously by others [41, 42]. 
To determine whether the HER2-overexpressing 
MCF7 cells display intrinsic resistance to drugs that target 
ERα, equal numbers of negative control parental, HER2 wt 
and HER2 insYVMA cells were cultured in the presence 
of fulvestrant as indicated (Figure 6C). After 10 days, 
MCF7 HER2 insYVMA displayed the highest colony 
outgrowth in the presence of fulvestrant. Interestingly, 
MCF7 HER2 wt cells showed only a slightly increased 
outgrowth in comparison to negative control cells, but a 
much more reduced outgrowth in comparison to MCF7 
HER2 insYVMA cells (Figure 6C).
These observation show that increased expression 
of HER2 wt only moderately increases intrinsic resistance 
of ER+/HER2+ breast cancer cells to endocrine therapy, 
supporting the notion that intrinsic resistance to ERα-
targeting drugs in ER+/HER2+ breast cancer patients 
might often be driven by HER2 mutants. 
Neither HER2 wt nor constitutively active HER2 
insYVMA can protect ER+ breast cancer cells 
from carfilzomib or bortezomib-induced cell 
death
To examine whether PIs can act against ERα+/
HER2+ breast cancer cells that express a constitutively 
active HER2 mutant that confers resistance to trastuzumab 
and lapatinib and intrinsic resistance to endocrine therapy, 
MCF7 HER2 insYVMA [40], MCF7 HER2 wt [40] 
and parental MCF7 cells were cultured in the presence 
of various carfilzomib or bortezomib concentrations as 
indicated. Induction of cell death upon carfilzomib and 
bortezomib treatment was assessed by quantification 
of SubG1 cells (Figure 7A, 7B, left+middle panel) and 
by colony-forming assays (Figure 7A, 7B, right panel). 
Notably, all cells were killed after 9 days when cultured 
in the presence of 250 nM carfilzomib (Figure 7A, right 
panel) or 25 nM bortezomib (Figure 7B, right panel). 
Immunoblotting demonstrated that both carfilzomib 
and bortezomib increased levels of BDP1 (Figure 7C). 
At the same time we observed markedly decreased 
HER2 phosphorylation and inhibition of the downstream 
pathways PI3K/Akt and Ras/MAPK, as indicated by 
decreased levels of p-HER2Tyr1248, p-HER2Tyr1221/1222, 
p-AktSer473 and p-ERK1/2 (Figure 7C). In the experiments 
above we also detected markedly decreased expression 
of ERα in response to carfilzomib and bortezomib 
(Figure 2B, 2D). These observations therefore indicate that 
carfilzomib and bortezomib efficiently inhibit the activity 
of both HER2 and ERα. In addition, both proteasome 
inhibitors strongly decreased EGFR and led to increased 
phosphorylation of p38 (Figure 7C).
Collectively, these results show that PIs potently 
decrease HER2 phosphorylation and activity, thereby 
attenuating downstream signaling pathways such 
as PI3K/Akt and Ras/MAPK that confer endocrine 
therapy resistance and estrogen-independence in ER+ 
breast cancer [18, 19]. In addition, PIs also induce 
dephosphorylation and inactivation of constitutively active 
HER2 that is resistant to trastuzumab and lapatinib. PIs 
might therefore be a potent treatment option for ERα+/
HER2+ breast tumors and breast cancer patients with 
mutated HER2.
Carfilzomib and bortezomib act in concert with 
lapatinib to inhibit HER2 activity and to induce 
cell death in ER+/HER2+ breast cancer cells 
PIs stabilize BDP1 that dephosphorylates HER2 and 
thereby revert it into an inactive state, while commonly 
used anti-HER2 agents exert their effects through other 
mechanisms (Figure 4C). We therefore investigated next 
whether PIs and lapatinib can cooperate to inhibit HER2 
activity. 
First we determined which concentrations of 
lapatinib are needed to induce growth arrest in BT474 
cells as assessed by colony-forming assays (Figure 8A, 
left panel). Lapatinib concentrations ≥ 50 nM markedly 
reduced colony outgrowth (Figure 8A, left panel). 
Immunoblotting demonstrated that lapatinib concentrations 
≥ 50 nM suppressed HER2 autophosphorylation and 
inhibited Akt, as indicated by decreased levels of 
p-HER2Tyr1248, p-HER2Tyr1221/1222 and p-AktSer473 (Figure 8A, 
right panel). 
To address the question whether PIs and 
lapatinib cooperate to inhibit HER2 activity, BT474 
cells were cultured in the presence of sublethal 
concentrations of carfilzomib, bortezomib or lapatinib 
either alone or in combination, and harvested at 
equal time points. Immunoblotting revealed that PIs 
combined with lapatinib led to stronger reduction 
of p-HER2Tyr1248, p-HER2Tyr1221/1222 and p-AktSer473 
than did the PIs or lapatinib alone (Figure 8B). 
Notably, BT474 cells treated with PIs exhibited increased 
levels of BDP1 and decreased levels of ERα (Figure 8B). 
Next, equal numbers of BT474 cells were cultured in 
the presence of carfilzomib, bortezomib or lapatinib for 
12 days, either alone or in combination. Lapatinib plus 
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bortezomib (Figure 8C, upper panel) and lapatinib plus 
carfilzomib (Figure 8C, lower panel) caused a stronger 
decrease in colony outgrowth than if the drugs were 
applied alone. Induction of cell death upon lapatinib, 
carfilzomib and bortezomib treatment was assessed by 
quantification of SubG1 cells (Figure 8D). The number of 
SubG1 cells detected after sublethal treatment either with 
carfilzomib plus lapatinib or bortezomib plus lapatinib 
nearly corresponds to the sum of SubG1 cells that were 
detected when these drugs were administrated alone.
Carfilzomib and bortezomib cause cell death in 
ER+/HER2-amplified breast cancer cells with 
acquired resistance to lapatinib
To determine whether PIs have the potential 
to inhibit outgrowth or to induce cell death in ER+/
HER2+ breast cancer cells with acquired resistance to 
lapatinib, we first developed lapatinib-resistant BT474 
cells by culturing them in the presence of lapatinib for 
10–12 weeks. Consistant with previous reports [15–17] 
immunoblotting showed that BT474 cells cultured in the 
permanent presence of lapatinib (referred here as BT474 
LR.) displayed increased expression of ERα in comparison 
to their non-treated counterparts (BT474 p.) (Figure 9A, 
upper left panel). Induction of cell death upon lapatinib 
treatment was assessed by quantification of SubG1 cells 
(Figure 9A, right panel) and by colony-forming assays 
(Figure 9A, left lower panel). After 12 days of lapatinib 
treatment significant differences in the numbers and 
outgrowth of colonies between BT474 LR. and BT474 
p. cells were observed (Figure 9A, left lower panel) and 
BT474 LR. cells formed colonies even in the presence of 
lapatinib. Furthermore BT474 LR. cells exhibited around 
25–35% less cell death in response to lapatinib than 
BT474 p. (Figure 9A, right panel).
Figure 6: Establishment of fulvestrant-resistant ERα-positive breast cancer cells that express a constitutively active 
HER2 mutant that is resistant to inhibition by trastuzumab and lapatinib. (A) MCF7 cells were retrovirally transduced to 
express HER2 wild-type (wt) or the constitutively active HER2 mutant insYVMA [40]. After selection, surviving cells and parental MCF7 
cells were fixed and expression of HER2 was evidenced by immunohistochemical staining. Bar 50 µm. (B) Extracts from the indicated cells 
were analyzed by immunoblotting with the indicated antibodies. (C) Equal numbers of negative control parental and MCF7 cells stably 
expressing HER2 wt or HER2 insYVMA were seeded on 6-well culture plates and treated with the indicated fulvestrant concentration. 
After 11 days cells were fixed and stained.
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Figure 7: Neither enforced expression of HER2 wt nor constitutively active HER2 insYVMA can protect ER+ breast 
cancer cells from carfilzomib or bortezomib induced cell death. (A) Carfilzomib and (B) bortezomib induce cell death in a 
time-dependent manner. Parental, HER2 wt or HER2 insYVMA MCF7 cells were cultured in the presence or absence of the indicated 
carfilzomib or bortezomib concentrations. The percentage of SubG1 cells was evaluated at different time points using propidium iodide 
staining and flow cytometry (left and middle panel). Mean values ± s.d. of three independent experiments are presented. Equal numbers of 
HER2 wt, HER2 insYVMA and negative control parental MCF7 cells were seeded on 12-well culture plates and treated with the indicated 
carfilzomib or bortezomib concentrations (right panels). After 9 days cells were fixed and stained. (C) MCF7 cells stably expressing HER2 
wt or HER2 insYVMA and negative parental control cells were cultured with the indicated carfilzomib and bortezomib concentrations for 
32 hours. Western blots of protein lysates were probed with the indicated antibodies.
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Next we investigated the potential of PIs to down-
regulate ERα expression and to inhibit HER2 activation 
in BT474 LR. cells. For this purpose BT474 LR. cells 
were cultured either in the absence or presence of PIs as 
indicated, and lysed at equal time points. Immunoblotting 
showed that carfilzomib and bortezomib strongly reduced 
ERα expression and caused inhibition of HER2 and its 
downstream target Akt, as indicated by decreased levels of 
p-HER2Tyr1248, p-HER2Tyr1221/1222 and p-AktSer473 (Figure 9B). 
Induction of cell death upon lapatinib, carfilzomib or 
bortezomib treatment was assessed by colony-forming 
assays (Figure 9C upper+middle panel) and quantification 
of SubG1 cells (Figure 9C lower panel). Notably, no 
surviving cells could be detected when cultured in the 
presence of 250 nM carfilzomib or 25 nM bortezomib 
(Figure 9C). Thus, these findings demonstrate that 
carfilzomib and bortezomib are able to disrupt HER2/ERα 
cross-talk and to induce cell death in HER2+/ER+ breast 
cancer cells with aquired resistance to lapatinib. A model 
of how PIs might interfere with bi-directional HER2/ERα 
signaling pathways that lead to lapatinib resistance is 
illustrated in Figure 10.
PIs decrease ERα levels and inhibit HER2 
phosphorylation comparably to fulvestrant plus 
lapatinib, however additionally induce caspase 
and PARP1 cleavage
The results of this study suggest that PIs efficiently 
inhibit ERα/HER2 cross-talk pathways through blocking 
ERα expression, as well as through inhibiting HER2 
activation via stabilization of BDP1, which leads to the 
death of ER+/HER2+ breast cancer cells. Thus PIs might 
be useful for clinical application. 
We therefore addressed the question of whether PIs 
have comparable or even stronger abilities to block ERα/
HER2 cross-talk pathways than drugs commonly used to 
treat breast cancer. To this end BT474 were cultured in 
the presence of lapatinib at concentrations that suppressed 
HER2 autophosphorylation and inhibited Akt (Figure 8A, 
right panel) together with combinations of fulvestrant, 
bortezomib and carfilzomib as indicated. After treatment 
all cells were harvested at equal time points. Notably, 
fulvestrant was given 4 hours before PIs and lapatinib to 
ensure that ERα is first degraded by the proteasome. 
Immunoblotting revealed that PIs alone reduced 
HER2 phosphorylation to a similar or even stronger 
extent than did lapatinib, as indicated by p-HER2Tyr1248 
and p-HER2Tyr1221/1222 (Figure 11A). PIs also reduced ERα 
levels to a comparable extent compared to fulvestrant 
(Figure 11A). However BT474 cells treated with PIs plus 
fulvestrant resulted in a stronger decrease in ERα levels 
than when fulvestrant and PIs were applied separately 
(Figure 11A). After 24 hours caspase and PARP1 cleavage 
appeared only in BT474 cells treated with PIs (Figure 
11A). The number of SubG1 cells detected after treatment 
with either PIs alone or in combination with lapatinib 
plus fulvestrant were nearly equivalent whereas treatment 
with fulvestrant plus lapatinib alone resulted in a later 
induction and lower number of SubG1 cells (Figure 11B). 
Consistently in colony-forming assays, bortezomib and 
carfilzomib caused a stronger decrease in colony outgrowth 
than fulvestrant plus lapatinib and combining fulvestrant 
plus lapatinib treatment with bortezomib and carfilzomib 
had an equivalent effect in these assays as bortezomib and 
carfilzomib administrated alone (Figure 11C). 
Collectively these data suggest that PIs have 
superior abilities to inhibit ERα/HER2 cross-talk pathways 
and thereby to suppress the growth of breast cancer cells 
compared to fulvestrant plus lapatinib. 
DISCUSSION
In ER+/HER2+ breast tumors, ERα and HER2 
synergize to allow breast cancer cells to escape from 
both anti-ERα and anti-HER2 targeted therapies. Thus, 
ERα circumvents the effects of anti-HER2 drugs and 
chemotherapy whereas HER2 signaling causes endocrine 
resistance. 
Here we report that carfilzomib and 
bortezomib markedly inhibit bi-directional HER2/
ERα signaling pathways in HER2+/ER+ breast 
cancer cells. Both PIs suppress ERα expression, 
inhibit HER2 activity and subsequently suppress the 
HER2 downstream pathway PI3K/Akt. HER2 and 
increased activation of the PI3K/Akt pathway are 
Figure 8: Carfilzomib and bortezomib act in concert with lapatinib to inhibit HER2 activity and to induce cell death 
in ER+/HER2+ breast cancer cells. (A) Equal numbers of BT474 cells were seeded on 12-well culture plates and treated with the 
indicated lapatinib concentrations. After 10 days cells were fixed and stained (left panel). BT474 cells were cultured in the presence of the 
indicated lapatinib concentrations for 32 hours. Western blots of protein lysates were probed with the indicated antibodies (right panel). 
(B) BT474 cells were cultured in the absence or in the presence of the indicated concentrations of lapatinib, bortezomib or both drugs 
together (left panel) or BT474 cells were cultured in the absence or presence of the indicated concentrations of lapatinib, carfilzomib 
or in combination (right panel). After 30 hours cells were harvested. Western blots of the protein lysates were probed with the indicated 
antibodies. (C) Equal numbers of BT474 cells were seeded on 6-well culture plates and cultured either with or without the indicated 
lapatinib, bortezomib or carfilzomib concentrations. After 12 days cells were fixed. Macroscopic photos are shown of the fixed cell colonies 
for BT474 cells treated with lapatinib, bortezomib and lapatinib plus bortezomib (upper panel) and lapatinib, carfilzomib and lapatinib plus 
carfilzomib (lower panel). Bar 100 µm. (D) To determine the induction of cell death relative to the applied lapatinib and or bortezomib/
carfilzomib concentrations equal numbers of BT474 cells were seeded on 12-well culture plates and cultured in the absence or in the 
presence of the indicated drug concentrations for 5 days. The percentage of SubG1 cells was evaluated using propidium iodide staining and 
flow cytometry. Mean values ± s.d. of three independent experiments are presented. 
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Figure 9: Carfilzomib and bortezomib induce cell death in ER+/HER2-amplified breast cancer cells that have acquired 
resistance to lapatinib. (A) BT474 cells were cultured in the absence or presence of lapatinib concentrations > 75 nM for 9 weeks and 
15 passages. Untreated parental (BT474 p.) and BT474 cells which survived and continued to grow in the presence of lapatinib (BT474 
LR.) were harvested. Protein lysates were assayed by immunoblotting for the level of ERα expression. β-actin served as loading control 
(left upper panel). Equal amounts (5 × 103) of BT474 p. and BT474 LR. cells were seeded per well on 6-well culture plates and cultured in 
the presence of 100 nM lapatinib. After 12 days cells were either fixed and stained (left lower panel) or cells were harvested after 5 days to 
determine induction of cell death. The percentage of SubG1 cells was evaluated using propidium iodide staining and flow cytometry. Mean 
values ± s.d. of three independent experiments are presented (right panel). P-values < 0.05 are indicated by asterisks. (B) BT474 LR. cells 
were cultured in presence of the indicated lapatinib, bortezomib or carfilzomib concentrations. Western blots of protein lysates were probed 
with the indicated antibodies. (C) Equal amounts of BT474 p. and BT474 LR. cells were seeded on 6-well culture plates and cultured 
either with or without the indicated concentrations of lapatinib, bortezomib or carfilzomib, respectively. For colony forming assay the cells 
were fixed and stained after 12 days cells (upper panel). Macroscopic photos of the fixed cell colonies are shown in the middle panel. Bar 
100 mm (middle panel). To determine the induction of cell death cells were harvested after 5 days. The percentage of SubG1 cells was 
evaluated using propidium iodide staining and flow cytometry. Mean values ± s.d. of four independent experiments are presented (lower 
panel). P-values < 0.05 are indicated by asterisks.
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major executors of endocrine resistance [18, 19]. 
Notably, we found that combined treatment of the ER+/
HER2+ breast cancer cell line BT474 with fulvestrant 
plus lapatinib was not as efficient as PIs in inducing cell 
death (Figure 11A–11C).  Furthermore, we observed that 
both PIs stabilize the HER2-specific tyrosine phosphatase 
BDP1 (Figure 2B, 2D), which is required for PI-mediated 
inhibition of HER2 and Akt activation as well as increased 
sensitivity to PI-induced cell death (Figure 5B–5D). 
Thereby, PIs suppress the activity of even a constitutively 
active HER2 variant that causes resistance to trastuzumab 
and lapatinib (Figure 7C). 
These findings clearly demonstrate that PIs 
disrupt the cross-talk between HER2 and ERα signaling 
pathways, through mechanisms that differ from current 
therapeutic regimens and therefore might expand 
treatment opportunities for ER+/HER2+ and possibly 
also for other groups of breast cancer patients by breaking 
therapy resistance (Figure 4C and Figure 11). 
Our data suggest that patients with resistance to 
HER2-targeted therapies also should benefit from PI 
treatment independent of their HR status. Futhermore, 
carfilzomib and bortezomib markedly decrease the 
phosphorylation status of a constitutively active HER2 
mutant that is resistant to trastuzumab and lapatinib 
[40], suggesting that proteasome inhibitors could be 
an interesting therapeutic opportunity for breast cancer 
patients with mutated HER2 variants that are resistant 
to commonly used anti-HER2 drugs. HER2 somatic 
mutations represent an alternative mechanism to activate 
HER2 breast cancer [43]. The majority of HER2 somatic 
mutations in breast cancer patients are activating 
mutations that likely drive tumorigenesis with an overall 
HER2 mutation rate of approximately 1.6% in breast 
cancers without HER2 amplification [43]. The frequency 
of somatic HER2 mutations is considerably higher in 
patients who are refractory to anti-HER2 therapies. For 
example, HER2 mutations were found in six of 36 patients 
(16.7%) refractory to anti-HER2 therapies [44]. The TKI 
neratinib is actually under investigation for patients with 
mutated HER2 and was shown to inhibit several HER2 
mutations with resistance to trastuzumab an/or lapatinib 
in cell culture experiments [40, 43].
We predict that PIs might have advantages over 
TKIs, because the mechanisms that lead to resistance 
to HER2-targeted therapies such as up-regulation of 
other growth factors or HER2/ERα cross-talk signalling 
pathways are also likely to attenuate the efficiency of 
new TKIs that target HER2 mutations. PIs on the other 
hand affect HER2+ breast cancer cells through multiple 
mechanisms and counteract HER2 activation through 
different mechanisms compared to TKIs for example 
through stabilizing the PEST-type protein tyrosine 
phosphatase BDP1 as we show here (Figure 4C, Figure 5). 
It is therefore conceivable that a stronger suppression 
of HER2 could possibly be achieved if both drugs are 
combined.
Several in vitro studies and clinical trials strongly 
suggest that ERα co-expression attenuates the efficiency 
of anti-HER2 drugs such as trastuzumab and lapatinib 
[45]. However, a variety of other mechanisms leading to 
intrinsic or aquired resistance to HER2-targeting therapies 
that are independent of ERα status have been observed 
among HER2+ breast cancer patients [46], including low 
PTEN expression, oncogenic PI3CA mutations [47], up-
regulation of growth factor receptors such as other HER-
family members, IGF-R1 [48], EphA2 [49], Met [50] 
and Axl [51]. Thus, in ongoing studies we are focusing 
Figure 10: Schematic model of how proteasome inhibitors disrupt bi-directional HER2/ERα cross-talk signaling 
pathways in lapatinib-resistant ER+/HER2+ breast cancer cells.  Schematic overview of how PIs might counteract mechanisms 
that lead to lapatinib resistance in ERα+/HER2+ breast cancer cells, based on the results of this report and the literature. Continued 
activation of HER2 has a causal role in tumorigenesis, lead to tumor progression [1]. Aberrant signaling through HER2 and other members 
of the HER-family mediates endocrine resistance in ERα positive breast cancer [18, 19], while preclinical and clinical studies revealed 
that ERα co-expression attenuates the efficiency of anti-HER2 therapies [8, 9, 12, 13, 14]. Previously, published reports and our own 
observations demonstrate that in ERα and HER2-positive breast cancer cells that are initially sensitive to lapatinib, increased expression 
of ERα and enhanced ERα signaling is evident upon acquisition of resistance to lapatinib [15]. Thus, up-regulation of ERα expression 
and/or activity can function as an escape mechanism that leads to resistance to anti-HER2 therapy in HER2+/ER+ breast cancer patients. 
Thus, in HER2+/ER+ breast cancer cells, either ERα or HER2 can promote proliferation and survival. These studies and our observations 
demonstrate that concomitant inhibition of both HER2 and ERα is needed to achieve the best antitumor activity in ER+/HER2+ breast 
cancer. Our experiments demonstrate that carfilzomib and bortezomib strongly reduce phosphorylation and activation of HER2 most likely 
through protecting HER2-specific PEST protein tyrosine phosphatases such as BDP1 from proteasomal destruction. Additionally, both 
PIs strongly reduce expression of ERα protein expression. Thus, PIs might be effective in the treatment of HER2+/ERα+ breast cancer by 
disrupting bi-directional HER2/ERα cross-talk signaling pathways.
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Figure 11: PIs decrease ERα levels and inhibit HER2 autophosphorylation to a similar extent as fulvestrant plus 
lapatinib, but PIs additionally lead to PARP1 and caspase cleavage. (A) BT474 cells were cultured in the absence or in the 
presence of the indicated concentrations and combinations of lapatinib, fulvestrant, carfilzomib and bortezomib. Where fulvestrant was 
used, it was administrated 4 hours before treatment with other drugs. After 30 hours cells were harvested. Western blots of the protein lysates 
were probed with the indicated antibodies. (B) To determine the induction of cell death in response to the indicated drug combinations 
equal numbers of BT474 cells were seeded on 12-well culture plates and cultured in the absence or in the presence of the indicated drug 
concentrations. The percentage of SubG1 cells was evaluated at different time points using propidium iodide staining and flow cytometry. 
Mean values ± s.d. of three independent experiments are presented. (C) Equal numbers of BT474 cells were seeded on 6-well culture 
plates and cultured either with or without the indicated drug combinations. After 8 days cells were fixed. Macroscopic photos are shown 
of the fixed cell colonies for BT474 cells either (a) untreated or treated with (b) lapatinib [125 nM] plus fulvestrant [1 µM], (c) bortezomib 
[30 nM], (d) bortezomib [30 nM] plus lapatinib [125 nM] plus fulvestrant [1 µM] or (e) carfilzomib [125 nM] and (f) carfilzomib [125 nM] 
plus lapatinib [125 nM] plus fulvestrant [1 µM]. Bar 100 µm. 
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on whether PIs also inhibits activation of other growth 
factor receptors like IGF-R1, FGFR1, FGFR2, Met and 
Axl that have been implicated in resistance to lapatinib 
[39] and which might be also associated with resistance 
to neratinib.
Our data indicate that PIs should also therapeutically 
target endocrine-resistant ER+/HER2- breast cancer. 
Frequent causes for intrinsic or aquired endocrine 
resistance in ER+/HER2- breast cancer include increased 
growth factor receptor signaling that results in ligand-
independent ERα activation, genomic alterations 
involving the ERα gene ESR1 such as ESR1 gene re-
arrangements with other genes, ESR1 amplifications and 
ESR1 recurrent point mutations [19]. Recurrent ERα 
mutations, ERα fusion proteins or postranscriptional 
modifications of ERα can circumvent the binding of 
inhibitory drugs to ERα or lead to constitutively active/
ligand-independent ERα proteins thereby making breast 
cancer cells resistant to drugs such as SERMs (e.g. 
tamoxifen) and AIs. Carfilzomib and bortezomib strongly 
suppress ERα protein expression and markedly reduce 
ERα levels [32]. We assume that PIs will have advantages 
over therapeutic regimens that simply affect ERα activity, 
such as aromatase inhibitors (AIs), SERMs and SERDs in 
patients with ERα mutations or with deregulated growth 
factor receptor signaling due to HER2-amplification or 
increased expression of other growth factors. In these 
patients drugs that solely target ERα activity cause 
activation of survival mechanisms and must therefore be 
combined with a second drug to suppress rescue pathways 
such as PI3K/Akt/mTOR and thereby to reverse or to 
avoid endocrine resistance. In contrast, PIs block ERα 
expression and concomitantly suppress survival pathways 
such as PI3K/Akt. Together our observations suggest that 
PIs might be a therapeutic option for endocrine resistant 
ER+ breast cancer patients, independently of whether 
endocrine resistance is mediated by deregulated growth 
factor receptor signaling or by ERα mutations.
The results from a recently reported randomized 
phase II trial are consistant with our suggestion that PIs can 
overcome endocrine therapy resistance. In this study, AI-
resistant HR+ metastatic breast cancer patients were treated 
with fulvestrant alone or in combination with bortezomib 
[52]. This trial demonstrated a significantly reduced rate of 
disease progression and significantly improved 12 month 
progression-free survival (PFS) rates in the fulvestrant 
plus bortezomib treated patients compared to those being 
treated with fulvestrant alone [52]. This trial was based 
on in vitro studies showing that fulvestrant promotes the 
accumulation of toxic ER aggregates in the cytoplasm that 
are normally cleared by the proteasome. Inhibition of the 
proteasome by combining fulvestrant with bortezomib was 
reasoned to enhance toxicity by increasing the amount of 
ER aggregates [53]. However the exact mechanisms by 
which bortezomib affects ER+ breast cancer cells within 
patients are unknown. 
In contrast to a previously published report [53], 
we found that treatment of BT474 cells with PIs and 
fulvestrant caused a stronger reduction of ERα levels than 
if fulvestrant or PIs were administered alone (Figure 11A). 
A possible explanation for this discrepancy might be that 
the chronological order in which fulvestrant and PIs are 
added to cells determines the effect upon ERα expression. 
We administered fulvestrant 4 hours before the PIs 
were added. It is therefore conceivable that ERα was first 
degraded by the proteasome, and after PIs were added the 
ERα expression was blocked and thereby no new ERα 
could further be produced. Interestingly, in the clinical 
trial to compare the efficiency of fulvestrant alone or in 
combination with bortezomib, patients in the fulvestrant 
+ bortezomib arm received fulvestrant before bortezomib 
was administered [52]. Our results therefore suggest 
that the successful outcome of this clinical trial was 
probably due to a stronger suppression of ERα expression 
in the fulvestrant + bortezomib arm rather than through 
accumulation of toxic ER aggregates. Thus, further clinical 
studies are required to gain more information about how 
PIs exactly act on breast cancer cells within patients. 
These trials should give insights into which patients 
would have benefit from PIs and which combinations of 
PIs with other drugs might be useful. Furthermore the 
chronological order in which PIs are administered with 
other drugs might have a decisive influence on the success 
or failure of treatment. 
Treatment of patients with bortezomib has often 
been limited due to high toxicity. However, clinical 
trials performed with carfilzomib in multiple myeloma 
patients showed a more favourable side effect profile 
compared to bortezomib [33]. Our results suggest that 
carfilzomib might have the potential to improve treatment 
opportunities for a variety of breast cancer patients. As a 
logical next step, an early phase clinical trial of carfilzomib 
in advanced breast cancer is required.
MATERIALS AND METHODS
Plasmids, shRNAs, reagents and antibodies
The plasmids pBabe puro-ERBB2 (Addgene 
Plasmid # 40978) [40], pBabe puro-ERRB2 A775_
G776insYVMA (Addgene Plasmid # 40982) [40] and 
pBabe puro-gateway (Addgene Plasmid # 51070) [35] were 
gifts from Matthew Meyerson. Carfilzomib was purchased 
from Amgen, Thousand Oaks, CA, USA. Bortezomib was 
purchased from Janssen Cilag, Neuss, Germany. Lapatinib-
Ditosylat was purchased from Selleckchem, Munich, 
Germany, Fulvestrant was purchased from Sigma Aldrich, 
Taufkrichen, Germany. Antibodies for detection of ERα 
(D-12): sc-8005, β-actin (C-4): sc-47778, Akt (H-136): 
sc-8312, ERK1 (C-16): sc-93, p38 (C-20): sc-535, BDP1 
(B-6): sc-515058, p53 (DO-1): sc-126, EGFR (1005): 
sc-03 and Caspase-3 (E-8): sc-7272 were purchased 
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from Santa Cruz Biotechnology, Heidelberg, Germany. 
Antibodies for detection of HER2 (#2242), p-HER2Tyr1248 
(#2247), p-HER2Tyr1221/1222 (#2243), p-AktS473 (#9271), 
p-ERK1/2 (#9106), p-p38 (#4511), PARP1 (#9532) and 
Caspase-7 (#9492) were purchased from Cell Signaling 
Technology, Heidelberg, Germany. shRNA against human 
BDP1 (PTPN18) and non-targeted shRNA were purchased 
from Sigma Aldrich (Taufkirchen, Germany). BDP1 
(PTPN18) shRNA1: NM_014369/TRCN0000003044; 
shRNA2: NM_014369/ TRCN0000003045; shRNA3: 
NM_ 014369/TRCN0000003046; shRNA4: NM_014369/ 
TRCN0000003046; shRNA4: NM_014369/ TRCN 
0000381010; shRNA5: NM_014369/ TRCN0000382258; 
shRNA6: NM_014369/ TRCN0000380807; shRNA7: 
NM_014369/ TRCN0000381001; shRNA8: NM_014369/ 
TRCN0000381490; shRNA9: NM_ 014369/ TRCN0000 
380581; shRNA10: NM_014369/TRCN0000380069. 
Cell culture and viral transduction
MCF7 and T47D cells were purchased from ATCC, 
BT474 cells were purchased from CLS Cell Line Services 
GmbH (Heidelberg, Germany) and MDA-MB-361 
cells were purchased from Sigma Aldrich (Taufkirchen, 
Germany). MCF7 and T47D were maintained in RPMI 
supplemented with 10% fetal bovine serum (Takara 
Clontech, Heidelberg, Germany), 1% L-glutamine and 
1% penicillin/streptomycin. BT474 cells were maintained 
in Advanced DMEM/F12 (Takara Clontech, Heidelberg, 
Germany) supplemented with 10% fetal bovine serum 
(Takara Clontech, Heidelberg, Germany), 1% L-glutamine, 
1% penicillin/streptomycin and 50 mg/ml human insulin 
(Sigma Aldrich, Taufkirchen, Germany). The packaging 
cell line Phoenix GP was used for generation of retroviruses 
following standard calcium phosphate protocols. Cells 
were selected with puromycin. For all experiments pooled, 
transduced selected cell clones were used.
Other methods
Western blot analysis, FACS analysis and clonogenic 
assays were performed as previously described [54]. 
Immunohistological staining
Immunohistochemistry was performed by using the 
Hercep t-test (Dako, Glostrup, Denmark). Staining was 
performed on an immunostainer (Autostainer +; Dako, 
Glostrup, Denkmark) according to the manufacturer´s 
instructions. 
Cell cycle analysis
Cell cycle analysis was performed through 
direct DNA staining with propidium iodide. Cells were 
resuspended in hypotonic fluorochrome solution (50 mg/ml 
propidium iodide in 0.1% sodium citrate plus 0.1% 
TritonX-100 (Sigma Aldrich, Taufkirchen, Germany), than 
placed at 4°C in the dark for 1 hr before flow cytometry 
analysis.
Statistical analysis
Differences between experimental groups were 
assessed using the Student’s t test (Statistical Analysis 
System, Release 9.3). p values of < 0.05 were considered 
significant.
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